NFE2L2 and Mental deterioration: In summary, a demonstration of the bioavailability of active TT components and CQA metabolites from CAP, as well as possible NRF2 activation in this target human population, paves the way for future clinical studies using CAP and its evaluation as a treatment for cognitive decline.